{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:27:53Z","timestamp":1793726873499,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ebiom.2022.104321","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:18:17Z","timestamp":1668039497000},"page":"104321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2\/3 trial"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3346-1394","authenticated-orcid":false,"given":"Jeffrey L.","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gunsior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6583-2751","authenticated-orcid":false,"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewei","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cimbora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Wingerchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.C.","family":"Cree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104321_bib1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2022.104321_bib2","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B\u00a0lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ebiom.2022.104321_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol"},{"key":"10.1016\/j.ebiom.2022.104321_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fimmu.2019.00201","article-title":"The role of B cells and antibodies in multiple sclerosis, neuromyelitis optica, and related disorders","volume":"10","author":"Hausser-Kinzel","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2022.104321_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk2132","article-title":"Functional impairment of CD19+CD24hiCD38hi B cells in neuromyelitis optica spectrum disorder is restored by B cell depletion therapy","volume":"13","author":"Kim","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2022.104321_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12026-014-8542-z","article-title":"Complement in monoclonal antibody therapy of cancer","volume":"59","author":"Rogers","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.ebiom.2022.104321_bib7","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1038\/sj.onc.1207104","article-title":"Monoclonal antibody therapeutics and apoptosis","volume":"22","author":"Ludwig","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ebiom.2022.104321_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ebiom.2022.104321_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ebiom.2022.104321_bib10","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: Part 1","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ebiom.2022.104321_bib11","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ebiom.2022.104321_bib12","first-page":"107","article-title":"Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies","volume":"5","author":"Chen","year":"2016","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ebiom.2022.104321_bib13","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2014.04.005","article-title":"Single-cell trajectory detection uncovers progression and regulatory coordination in human B cell development","volume":"157","author":"Bendall","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104321_bib14","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood.V70.5.1316.1316","article-title":"Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development","volume":"70","author":"Loken","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2022.104321_bib15","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/brain\/awz106","article-title":"Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production","volume":"142","author":"Cotzomi","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.ebiom.2022.104321_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ebiom.2022.104321_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","volume":"25","author":"Agius","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.ebiom.2022.104321_bib18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: first approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ebiom.2022.104321_bib19","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104321_bib20","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2022.104321_bib21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/1352458515620934","article-title":"Placebo-controlled study in neuromyelitis optica\u2014ethical and design considerations","volume":"22","author":"Cree","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.ebiom.2022.104321_bib22","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000978","article-title":"Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder","volume":"8","author":"Marignier","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ebiom.2022.104321_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/art.38194","article-title":"The plasma cell signature in autoimmune disease","volume":"66","author":"Streicher","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ebiom.2022.104321_bib24","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc\u03b3RIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2022.104321_bib25","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ebiom.2022.104321_bib26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1467-842X.2001.tb00294.x","article-title":"How can I deal with missing data in my study?","volume":"25","author":"Bennett","year":"2001","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.ebiom.2022.104321_bib27","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ebiom.2022.104321_bib28","article-title":"A longitudinal brain magnetic resonance imaging study of neuromyelitis optica spectrum disorder","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2022.104321_bib29","doi-asserted-by":"crossref","first-page":"e3124","DOI":"10.1212\/WNL.0000000000010847","article-title":"Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder","volume":"95","author":"Lee","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2022.104321_bib30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:21:44Z","timestamp":1762456904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422005035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":30,"alternative-id":["S2352396422005035"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104321","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2\/3 trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Horizon Therapeutics plc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104321"}}